It’s only fair to share… Elacridar C34H33N3O5, 563.6 g/mol 依克立达;gw0918 UNII-N488540F94 143664-11-3 [RN] 143851-84-7 (maleate salt(1:1)) 143851-98-3 (monoHCl) 4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-[ACD/Index Name] 7582 AR7621300 N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide GF120918 Elacridar (GF120918) GF-120918 GG-918 GW-120918 GW-918 GF-120918A (HCl) GlaxoSmithKline (previously Glaxo Wellcome ) was developing elacridar, an inhibitor of the multidrug resistance transporter BCRP (breast cancer resistant protein), as an oral …